Print Page | Close Page

 
 

Persist AI

Address: 890 Embarcadero Dr,, West Sacramento, Sacramento, California. CA 95605
 
Country: USA
 
Sectors: Collaborations & Partnerships- R&D, Collaborations & Partnerships-Manufacture, Contract Manufacturing, Contract Research & Development, Consultancy
 
Website: http://www.persist-ai.com
 
- - -
 

About Us

Developing extended-release PLG drug formulations takes $10M+ and 5-10 years. We enable drug manufacturers and CROs to shorten formulation discovery time by 30-50% by utilizing our automation and machine learning platform.

 
- - -
 

Sectors

  • Collaborations & Partnerships- R&D
  • Collaborations & Partnerships-Manufacture
  • Contract Manufacturing
 
  • Contract Research & Development
  • Consultancy
 
- - -
 

Categories

  • Drug Development Services
  • Platform Technology-Drug Development
  • Robotics
  • Process Automation Technology
  • Artificial Intelligence
  • Formulation Development
  • Process Development
  • Drug Design
 
  • Sustained Release
  • Controlled Release
  • Injectables
  • Parenterals
  • Injectables-Long Acting
  • Solubility Enhancement
  • Bioavailability enhancement
  • Bioprocess Development
 
- - -
 

News

 
20th February 2026
 

CyanoCapture and Persist AI Announce partnership for the manufacture of for Oral Protein and Peptide Drugs

 

SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- CyanoCapture, the innovator in cyanobacteriabased oral drug delivery, and Persist AI, the leader in AI-driven robotic pharmaceutical formulation, today announced a strategic collaboration to jointly build a next-generation GMP manufacturing facility in the San Francisco Bay Area. The facility, expected to be operational by Q4 2026, will be the first of its kind to combine cyanobacteria culture and processing with robotic automation for clinical-scale production of novel oral protein and peptide therapeutics.

 
-
 
 
31st October 2024
 

Persist AI and Nivagen to Collaborate on AI-Driven Manufacturing Process for Long-Acting Injectable

 

The two companies intend to leverage their complementary expertise and technology to bring a novel long acting injectable and drug product manufacturing platform to market.



 


 


 


SACRAMENTO, Calif., Aug. 12, 2024 /PRNewswire/ -- Persist AI and Nivagen have announced a collaboration to co-develop a next-generation manufacturing process for long-acting injectable (LAI) drugs, using Persist's AI-based formulation technology and Nivagen's manufacturing capabilities. The collaboration aims to simplify and accelerate the development and approval of LAI drugs, which can provide sustained and controlled release of drugs over weeks or months, improving patient adherence and outcomes.


 
- - -
 
Printed: 16-Apr-2026 at 00:45:56 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com